FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeremy Steele

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Dean A Fennell; Jeremy P C Steele; Jonathan Shamash; Sarah E Slater; Michael T Sheaff; Paula Wells; Robin Rudd; Justin Stebbing
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.
Dean A Fennell; Jeremy P C Steele; Jonathan Shamash; Marie T Evans; Paula Wells; Michael T Sheaff; Robin Rudd; Justin Stebbing
Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.
Peter W Szlosarek; Astero Klabatsa; Arben Pallaska; Michael T Sheaff; Paul Smith; Tim Crook; Matthew J Grimshaw; Jeremy P C Steele; Robin Rudd; Frances R Balkwill; Dean A Fennell
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeremy Steele (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Dean A Fennell; Jeremy P C Steele; Jonathan Shamash; Sarah E Slater; Michael T Sheaff; Paula Wells; Robin Rudd; Justin Stebbing
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.
International journal of cancer. Journal international du cancer 2007;121(11):2575-7.
2007: Dean A Fennell; Jeremy P C Steele; Jonathan Shamash; Marie T Evans; Paula Wells; Michael T Sheaff; Robin Rudd; Justin Stebbing
Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.
Cancer 2007;109(1):93-9.
2006: Peter W Szlosarek; Astero Klabatsa; Arben Pallaska; Michael T Sheaff; Paul Smith; Tim Crook; Matthew J Grimshaw; Jeremy P C Steele; Robin Rudd; Frances R Balkwill; Dean A Fennell
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(23):7126-31.
2006: Astero Klabatsa; Michael T Sheaff; Jeremy P C Steele; Marie T Evans; Robin Rudd; Dean A Fennell
Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM).
Lung cancer (Amsterdam, Netherlands) 2006;51(1):53-9.
2005: Jeremy P C Steele
Prognostic factors for mesothelioma.
Hematology/oncology clinics of North America 2005;19(6):1041-52, vi.
2005: Jeremy P C Steele; Astero Klabatsa; Dean A Fennell; Arben Palläska; Michael T Sheaff; Marie T Evans; Jonathan Shamash; Robin Rudd
Prognostic factors in mesothelioma.
Lung cancer (Amsterdam, Netherlands) 2005;49 Suppl 1():S49-52.
2005: Jeremy P C Steele; Astero Klabatsa
Chemotherapy options and new advances in malignant pleural mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(3):345-51.
2003: Jonathan Shamash; Jeremy P C Steele; P Wilson; Maria L Nystrom; Wendy Ansell; R T D Oliver
IPM chemotherapy in cytokine refractory renal cell cancer.
British journal of cancer 2003;88(10):1516-21.
2003: Maria L Nystrom; Jeremy P C Steele; Jonathan Shamash; Frances Neville; R T D Oliver
Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial.
Melanoma research 2003;13(2):197-9.
2002: Jeremy P C Steele; R T D Oliver
Testicular cancer: perils of very late presentation.
Lancet 2002;359(9318):1632-3.
2002: Jeremy P C Steele
Prognostic factors in mesothelioma.
Seminars in oncology 2002;29(1):36-40.
2001: Jeremy P C Steele
Gemcitabine/carboplatin versus cisplatin/etoposide for patients with poor-prognosis small cell lung cancer: a phase III randomized trial with quality-of-life evaluation.
Seminars in oncology 2001;28(3 Suppl 10):15-8.
2001: Jeremy P C Steele; CA O'Doherty; Jonathan Shamash; Marie T Evans; Nicole Gower; Marc Tischkowitz; Robin Rudd
Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(4):497-9.
2000: Jeremy P C Steele; Jonathan Shamash; Marie T Evans; Nicole Gower; Marc Tischkowitz; Robin Rudd
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3912-7.
2000: Neil Ashman; Jeremy P C Steele; Michael T Sheaff; Robin Rudd; J Onwubalili
Membranous nephropathy resolving with treatment of bronchial carcinoid tumor.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2000;36(3):E15.
2000: Jeremy P C Steele; Robin Rudd
Malignant mesothelioma: predictors of prognosis and clinical trials.
Thorax 2000;55(9):725-6.